logo-loader

ImmunoPrecise Antibodies Ltd

Receive alerts
Market:
TSX-V
Market Cap:
$41.47 m
Price
0.61 CAD
Change
15.09%
52 weeks high
0.93
52 weeks low
0.45

Direct Access to our Principal Scientists
With three Principal Scientists on staff, and our founder who co-pioneered Single-Step cloning and our B-cell Select platform, we offer professional consultation and consulting services for your R&D needs.

A Personalized Approach to Your Most Difficult Projects
Project personalization starts with a dedicated Principal or Senior Scientist as your project lead; to help manage your project today as well as all of your future pipeline custom mAb development needs. Taking this approach enables us to rapidly build a constructive professional working relationship based upon project data driven communications and collaboration. Our belief in actively investing in our client relationships has greatly aided us and our clients grow over the past 25 years through successful, high quality project outcomes.

Proprietary Technologies to Rapidly Provide High Affinity mAbs
ImmunoPrecise uses proprietary and innovative inoculation and cloning technologies, as well as established expertise, to produce mAbs significantly faster than traditional methods of antibody production. With these capacities ImmunoPrecise has produced hundreds of mAbs, many of which are now being sold commercially through industry partners.

Adaptive Lab Operations Allowing for In Process Project Add-Ons
To service your most difficult projects, our lab operations have been structured around providing project flexibility with the ability for in-process project add-ons. Additionally, we have established specific client touchpoints to review preliminary project results and discuss any changes to project direction to help clients get the most out of their investment.

 

A Personalized Approach to Your Most Difficult Projects

Project personalization starts with a dedicated Principal or Senior Scientist as your project lead; to help manage your project today as well as all of your future pipeline custom mAb development needs. Taking this approach enables us to rapidly build a constructive professional working relationship based upon project data driven communications and collaboration. Our belief in actively investing in our client relationships has greatly aided us and our clients grow over the past 25 years through successful, high quality project outcomes.

Proprietary Technologies to Rapidly Provide High Affinity mAbs

IPA uses proprietary and innovative inoculation and cloning technologies, as well as established expertise, to produce mAbs significantly faster than traditional methods of antibody production. With these capacities IPA has produced hundreds of mAbs, many of which are now being sold commercially through industry partners.

Adaptive Lab Operations Allowing for In Process Project Add-Ons

To service your most difficult projects, our lab operations have been structured around providing project flexibility with the ability for in-process project add-ons. Additionally, we have established specific client touchpoints to review preliminary project results and discuss any changes to project direction to help clients get the most out of their investment.

 

 

OmniMouseOmniRatOmniFlic

OmniAb® Service Provider

ImmunoPrecise is pleased to be a new preferred OmniAb® service provider. We have successfully adapted our Rapid Prime immunization strategy and our antibody development platform to OmniAb® animals for delivery of a diverse repertoire of antigen-specific antibodies with an industry-leading timeframe.

The Platform

Ligand Pharmaceutical’s OmniAb® transgenic rodents – OmniRat®, OmniMouse® and OmniFlic® – produce highly diversified antibody repertoires and offer accelerated discovery of fully human antibodies that are naturally optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.

ImmunoPrecise’s proprietary immunization and development platform works directly with OmniAb® animals for human antibody discovery. Based on hybridoma technology, our platform includes isolation of clones from semi-solid medium.

We have the capability to perform a variety of immunization protocols with OmniAb® animals including protein, peptide, DNA, or whole cell immunization.

By establishing a collaborative workflow between the client, Ligand, and the breeding facility, we can take a project from a target sequence to immunization, fusion, screening and delivery of the desired antibody.

Let our team of experienced scientists work with you to customize your human antibody development campaign.

Hybridoma Development

We custom develop mAbs to an array of antigens including peptides, modified peptides, recombinant proteins, DNA plasmids, small molecules and anti-idiotypic antibodies.

Mouse Rapid Prime Monoclonal Antibody Development

Rapid Prime is ImmunoPrecise’s proprietary custom monoclonal antibody development service. This rapid immunization strategy saves weeks in development time. When coupled with our Single-Step cloning procedure, positive hybridoma cell lines are identified in 65 days. This rapid immunization procedure does not compromise on affinity. It consistently generates large numbers of IgG clones specific for antigen. Click here for more Rapid Prime information.

This popular choice for antibody development can be paired with 2 standard method mice which serve as a contingency plan. Contact us and ask about our “Rapid Prime plus Contingency” antibody design.

Standard Method Monoclonal Antibody Development in Mice & Rats

ImmunoPrecise’s custom standard monoclonal antibody development service is the gold standard in antibody development. Intraperitoneal injections and a choice of adjuvant is available to suit the client’s specific needs. When this traditional immunization procedure is coupled with our Single-Step cloning method, weeks are shaved off the timeline of monoclonal development. Click here for more Standard Method information.

For more information please click here 

 

Rabbit Monoclonal Antibodies

 

Recombinant

 

ImmunoPrecise is excited to offer custom Rabbit Monoclonal Antibody development service using RMAT (Recombinant Monoclonal Antibody Technology). This proprietary technology screens the immune repertoire of the rabbit creating the power to select the desired antibody directly from B cells.

The RMAT Advantage

High affinity antibodies without the traditional cell fusion step; avoids stability issues commonly associated with hybridomas
Recombinant antibody ensures preservation of genetic information
Both a monoclonal and polyclonal end product
Utilization of rabbit immune system to generate antibodies against different epitopes on the same antigen

For more infromation please click here 

 

Recombinant Protein Expression and Production

ImmunoPrecise is excited to offer recombinant protein expression and production services.  Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.

Recombinant Protein Services

Transient mammalian recombinant protein production in HEK293E and HEK293ES (N-linked glycosylation deficient) cells using the r-PEX platform.
Stable protein production in HEK293E and HEK293ES cells.
Recombinant protein production in Escherichia coli or Pichia pastoris.
Purification of (recombinant) proteins.
Recombinant antibody development and production via the r-Ab platform.

For more information please click here 

Cryostorage

Cryostorage

In the event of an emergency, it is crucial to have a secondary stock of your valuable biological materials stored at an alternative location. ImmunoPrecise provides you with a secure, off-site storage facility to safeguard your assets.  We have the capability to store cell lines, tissues, RNA, DNA, plasmid constructs, antibodies, and many other biological materials.

Storage Options

+4°C
-20°C
-80°C
-196°C (Liquid Nitrogen, LN­2)

For more information please click here 

Hybridoma Sequencing

ImmunoProtect™: Hybridoma Sequencing

Your monoclonal antibody (mAb) is extremely valuable, but hybridoma cell lines can become unstable over time and can stop secreting antibody. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your mAb recombinantly should your hybridoma cell line become unstable.

Click here for further information 

For more information on all the services offered please click here

For information on products please click here 

 

 

Canada & Netherlands

Jennifer Bath, Ph.D.
CHIEF EXECUTIVE OFFICER AND PRESIDENT

Jennifer holds a Ph.D. in Cellular and Molecular biology from North Dakota State University, and a Bachelor’s degree in Biology, with an emphasis on human genetics, from the University of Kansas. She began her career in academia, and moved into industry after a 15-year appointment as an Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute; whose mission is to prevent and treat neglected tropical diseases. Jennifer has broad experience in vaccine and therapeutic design, development and testing.

Dr. Bath served many guidance roles in industry including advising on the Economic Development Corporation’s Strategic Planning Initiatives, consulting biotechnology and pharmaceutical companies on strategic and operational business practices, and providing governance for workshops in technology entrepreneurship. She has established relationships with leaders in the fields of therapeutics and vaccinology, enhancing collaborative developments and partnerships in discovery.

Jennifer served in an executive role at Aldevron, LLC, as the Global Director of Client Relations, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services.

Lisa Helbling
CHIEF FINANCIAL OFFICER

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. Currently, she serves on the board of directors for HealthyDakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committees. Prior to joining the executive team, Lisa served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Chip Wheelock
CHIEF TECHNOLOGY OFFICER

As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing all information technology aspects of ImmunoPrecise Antibodies.  Mr. Wheelock works closely with the other members of the Executive Management team and unit business leaders to grow the company through the use of software and technology services. Using an active and practical approach, Mr. Wheelock directs all employees in the Information Technology departments to attain the company’s strategic goals and establishes the company’s information technology strategic plan.

Mr. Wheelock oversees all aspects of Information Technology where he provides leadership for continuous innovation of a wide array of technological systems across all of ImmunoPrecise’s businesses. He works closely with the individual business leaders to ensure that the technology and collaboration systems increase efficiencies and focuses on creating a competitive advantage through the innovative use of technology.  Mr. Wheelock brings a diverse background to ImmunoPrecise, he has held leadership positions within the software development and services industries over the past 25 years encompassing global ERP deployments, cloud transformations and building strategic line of business applications.  Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a Senior Global Technical Account Manager, where he drove both strategic and technical initiatives for many large organizations. Mr. Wheelock holds a Bachelor’s degree from the University of Kansas along with several industry and project management certifications.

Kari Graber
DIRECTOR OF GLOBAL PROJECT MANAGEMENT

Kari Graber serves as the Director of Global Project Management for ImmunoPrecise Antibodies and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC where she held a client relations management role for their antibody services platform. Kari holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology from North Dakota State University.

Jason Orloske
VP OF OPERATIONS

Jason Orloske serves as the Vice President of Operations for ImmunoPrecise and is responsible for operationalizing strategic initiatives and helping drive growth.  Jason is a transformational business leader with almost 20 years’ experience in project portfolio management and strategic delivery.  He partners with executives and senior management teams to completely uncover challenges and opportunities being faced, and develops a right-sized strategy that aligns with organizational vision.

Jason brings a diverse background to ImmunoPrecise.  Much of his career has been spent in the consulting space focused on creating operational efficiencies and mergers and acquisitions.  Most recently, Jason lead implementation management at WEX Health (health benefits SaaS platform), and Aldevron where he managed the project management office (PMO).  Jason holds a master’s degree in Project Management from the University of Mary in Bismarck, ND, where he also taught as an adjunct professor for two years after graduation.

Address

ImmunoPrecise Antibodies Ltd.
Vancouver Island Technology Park
Unit 3204-4464 Markham Street
Victoria, British Columbia,
V8Z 7X8, Canada

Tel: +1-250-483-0308
 

Please click here 

Investor Relations

For investor inquiries please contact:

Contact Financial,
Rob Gamley,
604-689-7422,
[email protected]